Market Overview

Why BioMarin Pharmaceutical Is Surging

Related BMRN
18 Stocks Moving In Thursday's Pre-Market Session
Rich Ross Shares His Biotech Trades
Biomarin Comes Up Short With Vosoritide (Seeking Alpha)
Watch These 5 Huge Put Purchases In Tuesday Trade
Barron's Picks And Pans: eBay, Shire, Samsung And More
Biotech Forum Daily Digest: Can Biotech Rebound? Jefferies Says Sector Undervalued; Spotlight On Kite Pharma (Seeking Alpha)

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) jumped over 14 percent on Friday, as a buyout rumor surfaced just ahead of an apparently routine conference call with analysts concerning its developmental drug programs.

Separately, Deutsche Bank's Robyn Karnauskas published a note on Friday raising her target 55 percent to $140.

BioMarin changed hands recently at $129.51, up $13.96. The stock is up 45 percent year to date.

Ben Harrington, a former business editor at the Daily Telegraph who now writes for the blog Betaville, cited unnamed sources on Thursday claiming that Ireland-based Shire PLC (ADR) (NASDAQ: SHPG) was "weighing a $65 billion merger with BioMarin."

Related Link: What Evercore Is Watching At BioMarin Pharmaceutical

The Novato, California-based BioMarin has a market capitalization of about $20.9 billion versus Shire's $40 billion cap.

Karnauskas' note focused on BioMarin's drug development, and didn't comment on Harrington's report. But she put the company's potential take-out value at $170 a share.

Data on several development programs will act as catalysts on the stock in the upcoming year, during which Karnauskas expects the shares will be volatile.

"Not everything in the pipeline needs to work for the stock to work, or to command and M&A premium," said Karnauskas, who reiterated a Buy rating.

A BioMarin conference call with analysts was slated to start at 10 a.m. Friday.

Latest Ratings for BMRN

Aug 2016Stifel NicolausMaintainsBuy
Aug 2016JP MorganMaintainsOverweight
Aug 2016JefferiesMaintainsBuy

View More Analyst Ratings for BMRN
View the Latest Analyst Ratings

Posted-In: biomarinAnalyst Color News Rumors Price Target Reiteration Analyst Ratings Movers


Related Articles (BMRN + SHPG)

View Comments and Join the Discussion!